NCT03895229View on ClinicalTrials.gov

The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

October 19, 2018

Study Completion Date

October 26, 2018

Conditions
Diabetes MellitusPharmacokineticsPharmacodynamics
Interventions
DRUG

Empagliflozin 10 MG Oral Tablet [Jardiance]

Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus

Trial Locations (1)

Unknown

Drug research centre, Cairo

All Listed Sponsors
collaborator

Drug Research Centre, Cairo, Egypt

OTHER

lead

Ain Shams University

OTHER

NCT03895229 - The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin | Biotech Hunter | Biotech Hunter